BRNS
Barinthus Biotherapeutics plc
NASDAQ: BRNS · HEALTHCARE · BIOTECHNOLOGY
$0.69
-6.95% today
Updated 2026-06-05
Market cap
$26.96M
P/E ratio
—
P/S ratio
3.80x
EPS (TTM)
$-1.29
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
Barinthus Biotherapeutics plc (BRNS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-78.74%
ROA
-23.20%
Debt/equity
0.17x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $6.85M | $-20.73M | -335.97% | -374.94% | -302.84% |
| 2020 | $4.82M | $-17.71M | -198.42% | -415.81% | -367.27% |
| 2021 | $268000.00 | $-50.87M | 100.00% | -16,873.51% | -18,979.48% |
| 2022 | $44.70M | $5.34M | 100.00% | -9.04% | 11.95% |
| 2023 | $802000.00 | $-73.35M | 100.00% | -10,463.09% | -9,145.51% |
| 2024 | $14.97M | $-61.07M | 100.00% | -454.07% | -408.00% |
| 2025 | $0.00 | $-66.58M | — | — | — |
Frequently asked questions
How much free cash flow does BRNS generate?
BRNS produced $-48.02M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BRNS's balance sheet healthy?
BRNS holds $70.46M in cash and equivalents against — in long-term debt, on $74.21M of shareholder equity. That debt is best read against the cash flow the business throws off each year.